Nalmefene: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), NICE (England) and SMC (Scotland) recommended or restricted nalmefene, while PBAC (Australia) and TLV (Sweden) did not recommend it.
Assessment has run over 7.4 years, from 7 Oct 2013 at SMC (Scotland) to 24 Mar 2021 at HAS (France).
No assessment is on file from PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
Nothing has been added since 2021; on this evidence the file is dormant.
4 distinct indication wordings are recorded for nalmefene by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 9 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess nalmefene, on 7 Oct 2013; PBAC (Australia) did not open a file until 2015 — a moderate spread of 1.8 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
HAS (France) is the only agency to have returned to nalmefene, recording 3 separate entries.
7 of the 18 agencies in this archive hold a record for nalmefene.
The full ledger for nalmefene reads 5 recommended, 2 not recommended, 1 no benefit and 1 superseded.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 24 Mar 2021 | Re-assessment following post-listing study results | SMR moderate | source |
| PBAC (Australia) | 2015 | Alcohol dependence | The PBAC did not recommend the listing of nalmefene for the treatment of alcohol dependenc… | source |
| TLV (Sweden) | 31 Mar 2015 | Selincro ingår inte i högkostnadsskyddet | rejection or exclusion | source |
| G-BA (Germany) | 19 Feb 2015 | Selincro — benefit assessment §35a | added benefit: not proven | source |
| NICE (England) | 26 Nov 2014 | NICE TA325 | recommended | source |
4 further decisions for nalmefene, across 3 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- nicotine — same ATC class N07B — Other nervous system
- buprenorphine — same ATC class N07B — Other nervous system
- buprenorphine / naloxone — same ATC class N07B — Other nervous system
- varenicline — same ATC class N07B — Other nervous system
- naltrexone — same ATC class N07B — Other nervous system
- alpelisib — also decided by HAS in 2021Q1
Coverage: 9 decisions for nalmefene from 7 agencies, 2013 to 2021. Data to 7 Sep 2026. ATC class N07B — Other nervous system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.